126 related articles for article (PubMed ID: 24038392)
1. Clinically significant missense variants in human GALNT3, GALNT8, GALNT12, and GALNT13 genes: intriguing in silico findings.
Hussain MRM; Nasir J; Al-Aama JY
J Cell Biochem; 2014 Feb; 115(2):313-27. PubMed ID: 24038392
[TBL] [Abstract][Full Text] [Related]
2. Clinically Significant Missense Variants in Human GALNT3, GALNT8, GALNT12, and GALNT13 Genes: Intriguing In Silico Findings. Muhammad Ramzan M. Hussain, Jamal Nasir, Jumana Yousuf Al-Aama.
J Cell Biochem; 2017 Oct; 118(10):3520. PubMed ID: 28792674
[No Abstract] [Full Text] [Related]
3. A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome.
Olauson H; Krajisnik T; Larsson C; Lindberg B; Larsson TE
Eur J Endocrinol; 2008 Jun; 158(6):929-34. PubMed ID: 18322299
[TBL] [Abstract][Full Text] [Related]
4. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
Frishberg Y; Topaz O; Bergman R; Behar D; Fisher D; Gordon D; Richard G; Sprecher E
J Mol Med (Berl); 2005 Jan; 83(1):33-8. PubMed ID: 15599692
[TBL] [Abstract][Full Text] [Related]
5. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Ichikawa S; Baujat G; Seyahi A; Garoufali AG; Imel EA; Padgett LR; Austin AM; Sorenson AH; Pejin Z; Topouchian V; Quartier P; Cormier-Daire V; Dechaux M; Malandrinou FCh; Singhellakis PN; Le Merrer M; Econs MJ
Am J Med Genet A; 2010 Apr; 152A(4):896-903. PubMed ID: 20358599
[TBL] [Abstract][Full Text] [Related]
6. A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.
Esapa CT; Head RA; Jeyabalan J; Evans H; Hough TA; Cheeseman MT; McNally EG; Carr AJ; Thomas GP; Brown MA; Croucher PI; Brown SD; Cox RD; Thakker RV
PLoS One; 2012; 7(8):e43205. PubMed ID: 22912827
[TBL] [Abstract][Full Text] [Related]
7. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
Ichikawa S; Imel EA; Sorenson AH; Severe R; Knudson P; Harris GJ; Shaker JL; Econs MJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4472-5. PubMed ID: 16940445
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
[TBL] [Abstract][Full Text] [Related]
9. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.
Ichikawa S; Lyles KW; Econs MJ
J Clin Endocrinol Metab; 2005 Apr; 90(4):2420-3. PubMed ID: 15687324
[TBL] [Abstract][Full Text] [Related]
10. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.
Topaz O; Shurman DL; Bergman R; Indelman M; Ratajczak P; Mizrachi M; Khamaysi Z; Behar D; Petronius D; Friedman V; Zelikovic I; Raimer S; Metzker A; Richard G; Sprecher E
Nat Genet; 2004 Jun; 36(6):579-81. PubMed ID: 15133511
[TBL] [Abstract][Full Text] [Related]
11. Recessive mutation in GALNT3 causes hyperphosphatemic familial tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis.
Albaramki J; Dmour H; Shboul M; Bonnard C; Venkatesh B; Odeh R
Turk J Pediatr; 2019; 61(1):130-133. PubMed ID: 31559735
[TBL] [Abstract][Full Text] [Related]
12. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
[TBL] [Abstract][Full Text] [Related]
13. Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3.
Joseph L; Hing SN; Presneau N; O'Donnell P; Diss T; Idowu BD; Joseph S; Flanagan AM; Delaney D
Skeletal Radiol; 2010 Jan; 39(1):63-8. PubMed ID: 19830424
[TBL] [Abstract][Full Text] [Related]
14. GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.
Chefetz I; Kohno K; Izumi H; Uitto J; Richard G; Sprecher E
Biochim Biophys Acta; 2009 Jan; 1792(1):61-7. PubMed ID: 18976705
[TBL] [Abstract][Full Text] [Related]
15. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
[TBL] [Abstract][Full Text] [Related]
17. GALNT12 is not a major contributor of familial colorectal cancer type X.
Seguí N; Pineda M; Navarro M; Lázaro C; Brunet J; Infante M; Durán M; Soto JL; Blanco I; Capellá G; Valle L
Hum Mutat; 2014 Jan; 35(1):50-2. PubMed ID: 24115450
[TBL] [Abstract][Full Text] [Related]
18. Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene.
Mahjoubi F; Ghadir M; Samanian S; Heydari I; Honardoost M
J Endocrinol Invest; 2020 Aug; 43(8):1125-1130. PubMed ID: 32125652
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Rafaelsen S; Johansson S; Ræder H; Bjerknes R
BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
[TBL] [Abstract][Full Text] [Related]
20. Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.
Yancovitch A; Hershkovitz D; Indelman M; Galloway P; Whiteford M; Sprecher E; Kılıç E
J Bone Miner Metab; 2011 Sep; 29(5):621-5. PubMed ID: 21347749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
